Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
The following section summarizes insights on Charles River Laboratories's Predicted EV / EBITDA Exit Multiple (FY+10):
No data available
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to Predicted EV / EBITDA Exit Multiple (FY+10) in the predictions category include:
Our estimate of the fair value EV / EBITDA Exit Multiple (FY+10) for a company.
The chart above depicts the distribution of Predicted EV / EBITDA Exit Multiple (FY+10) for companies operating in the Healthcare Sector in the Developed economic region. Over 1,120 companies were considered in this analysis, and 1,078 had meaningful values. The average Predicted EV / EBITDA Exit Multiple (FY+10) of companies in the Sector is 8.2x with a standard deviation of 6.8x. Please note that Sector and Industry values may differ from other sources, as no adjustments have been made.
Charles River Laboratories's Predicted EV / EBITDA Exit Multiple (FY+10) of 12.7x ranks in the 79.1% percentile for the Sector. The following table provides additional summary stats:
| Economic Risk Region | Developed |
| Total Constituents | 1,122 |
| Included Constituents | 1,078 |
| Min | 0.0x |
| Max | 39.1x |
| Median | 7.1x |
| Mean | 8.2x |
| Standard Deviation | 6.8x |
You can find companies with similar Predicted EV / EBITDA Exit Multiple (FY+10) using this stock screener.